AA
RNAM

ALPS Advisors’s Avidity Biosciences RNAM Stock Holding History

ALPS Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-70,573
Closed -$3.07M – 1077
2025
Q3 		$3.07M Buy
70,573
+5,549
+9% +$224K 0.02% 324
2025
Q2 		$1.85M Sell
65,024
-22,340
-26% -$666K 0.01% 377
2025
Q1 		$2.58M Sell
87,364
-9,111
-9% -$284K 0.02% 311
2024
Q4 		$2.81M Buy
96,475
+8,408
+10% +$351K 0.02% 297
2024
Q3 		$4.04M Buy
88,067
+13,460
+18% +$584K 0.03% 261
2024
Q2 		$3.05M Buy
74,607
+18,380
+33% +$527K 0.02% 283
2024
Q1 		$1.43M Buy
56,227
+5,554
+11% +$87K 0.01% 409
2023
Q4 		$459K Sell
50,673
-4,057
-7% -$27.1K ﹤0.01% 621
2023
Q3 		$349K Buy
54,730
+2,674
+5% +$23K ﹤0.01% 661
2023
Q2 		$577K Buy
52,056
+5,406
+12% +$67.8K 0.01% 586
2023
Q1 		$716K Buy
46,650
+9,731
+26% +$214K 0.01% 528
2022
Q4 		$819K Buy
36,919
+8,416
+30% +$125K 0.01% 519
2022
Q3 		$465K Sell
28,503
-1,022
-3% -$19.6K ﹤0.01% 605
2022
Q2 		$429K Buy
+29,525
New +$439K ﹤0.01% 637

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ALPS Advisors's RNAM Position: Q4 2025 in Review

ALPS Advisors sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 70,573 shares — an estimated $3.07M sold.

ALPS Advisors first reported a position in RNAM in Q2 2022 and held it in 14 quarters. The position peaked at $4.04M in Q3 2024. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • ALPS Advisors reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 70,573 Avidity Biosciences shares in Q4 2025, an estimated $3.07M.
  • ALPS Advisors first reported a position in Avidity Biosciences in Q2 2022 and held it in 14 quarters.
  • ALPS Advisors's Avidity Biosciences position peaked at $4.04M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.